News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Sacituzumab govitecan proves real-world survival benefits in metastatic breast cancer
19 Jan 2026
byStephen Padilla
A real-world study of the antibody-drug conjugate (ADC) sacituzumab govitecan in patients with HR+/ HER2- metastatic breast cancer (mBC) or metastatic triple-negative breast cancer (mTNBC) shows consistent survival outcomes as those seen in clinical trials.







